DPP4 and type 2 diabetes mellitus: Performed analysis of published articles suggest the plausible role of the genetic factors in the therapy response of common drugs for T2D treatment including polymorphisms of 31 genes in metformin response, polymorphisms of 8 genes in sulfonylureas/meglitinides response, polymorphisms of 12 genes in DPP-4 inhibitors response and polymorphisms of 5 genes in GLP1R agonists response.